TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02094547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New infant formula
Description: New infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breastfeeding
Description: Exclusive breastfeeding or less tan 25% formula intake
Study: NCT02785575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeProCalc algorithm
Description: Heparin and protamine dosage calculated by the algorithm HeProCalc
Study: NCT01569750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, Cohort 1
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2, Cohort 2
Description: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
Study: NCT00833183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Description: 80 mg/g cream one administration with incubation for 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Description: 80 mg/g cream one administration with incubation for 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Description: 80 mg/g cream one administration with incubation for 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL
Description: 80 mg/g cream one administration with incubation for 90 minutes
Study: NCT02224352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional neuromuscular electrical stimulation
Study: NCT01716091

Intervention type: PROCEDURE
Intervention: irrigation in the peritoneal cavity
Description: irrigation in the peritoneal cavity after uterine wall closed at cesarean
Study: NCT02585141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDIPLAST® (aspiration)
Description: The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incision
Description: Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
Study: NCT02546778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermosux RF
Description: The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
Study: NCT01613807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin LISPRO
Description: Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin, Long-Acting and Insulin
Description: Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Study: NCT02275845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control diet
Description: 2000 calories/day diet, with an adequate distribution of carbohydrates during the day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control diet
Description: 2000 calories/day diet, with an adequate distribution of carbohydrates during the day
Study: NCT03439345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg
Description: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
Study: NCT00742014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
Study: NCT03618927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily physical activity intervention
Study: NCT03159325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Circles
Description: See description in the arm description.
Study: NCT04532983

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of mesh prosthesis
Description: in the first group mesh was fixed in position with laparoscopic tacks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh placement without fixation
Description: mesh placement in preperitoneal space without fixation
Study: NCT04950387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Based in yoga, common load
Study: NCT04306913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: esmolol 250 mg in cardioplegia solution every 25 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Cardioplegic Solution
Description: 15 meq potassium added to cardioplegia solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Cardioplegic Solution
Description: 15 meq potassium added to cardioplegia solution
Study: NCT02629419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Oral lipid nanocrystal formulation of amphotericin B
Study: NCT01729091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous stem cell transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-Derived Lymphocyte Therapy
Description: Given IV
Study: NCT00888407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBV Screening - Small group educational session
Description: Small group HBV focused discussion with HBV screening resources.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition - Small group educational session
Description: Small group session with diet \& nutrition focused, topic related resources provided.
Study: NCT04145323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ICG microangiography
Description: Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
Study: NCT03184142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Student watch a 15-minute intimidation video (see arm description).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention. The students suture for 70 minutes
Study: NCT02862652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
Study: NCT03465085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Description: Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
Study: NCT03767400

Intervention type: DEVICE
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.

Intervention type: DEVICE
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.

Intervention type: DEVICE
Intervention: Skin Imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.

Intervention type: OTHER
Intervention: Facial Cleanser
Description: Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.

Intervention type: OTHER
Intervention: Facial Cleanser
Description: Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.

Intervention type: OTHER
Intervention: Facial Cleanser
Description: Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
Study: NCT04125771

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenac + HBB with hysteroscopy
Description: Giving Diclofenac + HBB with hysteroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenac + HBB with hysteroscopy
Description: Giving Diclofenac + HBB with hysteroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenav + placebo
Description: Giving Diclofenac + placebo with hysteroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diclofenav + placebo
Description: Giving Diclofenac + placebo with hysteroscopy
Study: NCT02587013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type A of uterine repair: In situ
Description: The uterine incision is closed with the uterus within the abdominal cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type B of uterine repair: Exteriorization
Description: The uterine incision is repaired with the exteriorization of the uterus
Study: NCT04301700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfullness and relaxation
Description: three arms: mindfullness and relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfullness and relaxation
Description: three arms: mindfullness and relaxation
Study: NCT02956122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone or equivalent steroid
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone or equivalent steroid
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone or equivalent steroid
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
Study: NCT04560777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP intervention
Description: The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents.
Study: NCT01165164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 115958D (lubricant eye drop)
Description: 1 drop in each eye at bedtime
Study: NCT04358614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib+antiviral therapy administration for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib 4 MG Oral Tablet
Description: Baricitinib+antiviral therapy administration for 2 weeks
Study: NCT00874562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Taken orally mixed with water or orange juice
Study: NCT01926197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: 5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.
Study: NCT03079037

Intervention type: DEVICE
Intervention: Stimulation
Description: Traditional deep brain stimulation
Study: NCT03652649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3:1 ratio Ketogenic diet
Description: Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
Study: NCT03403946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh blade
Description: Laryngoscopy with C-MAC PM in combination with Macintosh blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-Blade
Description: Laryngoscopy with C-MAC PM in combination with D-Blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation with C-MAC PM in combination with D-Blade
Study: NCT03102307

Intervention type: OTHER
Intervention: Not suitable for TAD
Description: Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done

Intervention type: PROCEDURE
Intervention: Suitable for TAD
Description: Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy

Intervention type: PROCEDURE
Intervention: Suitable for TAD
Description: Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
Study: NCT01323036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish oil: Total omega-3 fatty acids: 560-660 mg
Study: NCT00410059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily x 28 days
Study: NCT03138200

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood transfusion
Description: Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
Study: NCT02016664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
Study: NCT00413075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral belinostat
Description: oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
Study: NCT03443063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet
Study: NCT02137395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone administration, intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline administration intravenously
Study: NCT01477294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Malt dextrin (5 mg/kg body mass) twice a day during 4 days